Get the Stockscreener App
0.9807
2.90%
-0.0293
After Hours:
.99
0.0093
+0.95%
Oncolytics Biotech Inc stock is traded at $0.9807, with a volume of 1.24M.
It is down -2.90% in the last 24 hours and up +10.55% over the past month.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.
See More
Previous Close:
$1.01
Open:
$1.02
24h Volume:
1.24M
Relative Volume:
1.36
Market Cap:
$105.53M
Revenue:
-
Net Income/Loss:
$-20.31M
P/E Ratio:
-3.7078
EPS:
-0.2645
Net Cash Flow:
$-21.07M
1W Performance:
-20.91%
1M Performance:
+10.55%
6M Performance:
-5.70%
1Y Performance:
+33.98%
1-Day Range:
$0.9699
$1.04
1-Week Range:
$0.9699
$1.24
52-Week Range:
$0.3258
$1.51
Oncolytics Biotech Inc Stock (ONCY) Company Profile
Compare ONCY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ONCY
Oncolytics Biotech Inc
|
0.9807 | 108.68M | 0 | -20.31M | -21.07M | -0.2645 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.90 | 120.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.45 | 78.77B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
840.50 | 52.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
338.06 | 45.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
340.38 | 38.73B | 4.98B | 69.59M | 525.67M | 0.5197 |
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-25 | Initiated | Lake Street | Buy |
| Oct-06-22 | Initiated | Maxim Group | Buy |
| Feb-17-21 | Initiated | H.C. Wainwright | Buy |
Oncolytics Biotech Inc Stock (ONCY) Latest News
Breakout Zone: What is Oncolytics Biotech Incs 5 year growth outlookTake Profit & Fast Moving Stock Watchlists - baoquankhu1.vn
Stock Report: Is Oncolytics Biotech Inc forming a breakout pattern - baoquankhu1.vn
$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors - Cantech Letter
Record $2.5B Sector Start Spotlights Clinical Oncology Plays - Baystreet.ca
$170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium - PR Newswire
Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer Treatment - Investing News Network
Late-Stage Breakthroughs: How 2026’s Top Clinical Platforms Are Redefining Cancer Treatment - Cantech Letter
Performance Recap: What is Oncolytics Biotech Incs 5 year growth outlookJuly 2025 Macro Moves & Community Consensus Trade Alerts - baoquankhu1.vn
Registration-Ready: How 2026’s Clinical Leaders Are Beating Cancer Benchmarks - The AI Journal
Hard-to-Treat Cancers: How 2026’s Top Clinical Platforms Are Beating Industry Benchmarks - Baystreet.ca
Oncolytics Biotech Strengthens Leadership for Oncology Trials - Intellectia AI
Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks - Newswire Canada
THE RESILIENCE DOCTRINE: 5 Assets Securing the 2026 Sovereign Stack - The Globe and Mail
Trade Recap: What analysts say about SFBS stockBreakout Watch & Weekly High Return Forecasts - baoquankhu1.vn
Oncolytic Virotherapy Market - GlobeNewswire Inc.
Oncolytics Biotech Inc. (NASDAQ:ONCY) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Oncolytics Biotech (NASDAQ:ONCY) Director Bernd Seizinger Acquires 100,000 Shares - MarketBeat
Stocks In Play - Baystreet.ca
Stocks in play: Oncolytics Biotech Inc - Barchart.com
Oncolytics Biotech Inc - Baystreet.ca
Oncolytics Biotech Announces Results of Special Meeting of Shareholders - marketscreener.com
Oncolytics Biotech Shareholders Approve Redomiciliation to Nevada and New Incentive Plan - TipRanks
Oncolytics Biotech® Announces Results of Special Meeting of Shareholders - The Manila Times
Oncolytics Biotech Inc. Announces Approval of Shareholder Resolutions at Special Meeting - Quiver Quantitative
ONCY: All resolutions, including corporate moves and the 2026 Incentive Plan, were approved by shareholders - TradingView
Oncolytics Biotech Inc Announces Key Executive Appointments - TradingView
Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff - The Globe and Mail
Oncolytics Biotech® Appoints John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead Biostatistics - Sahm
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Oncolytics Biotech Inc. Appoints John McAdory as Executive Vice President of Strategy and Operations - marketscreener.com
The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era - The Manila Times
Oncolytics Biotech Bolsters Late-Stage Cancer Push With New Strategy and Biostatistics Leaders - TipRanks
The $69B Precision Pivot: Why Biomarker Platforms are Igniting a New Oncology Gold Rush - The Globe and Mail
THE SOVEREIGN MANDATE: 5 Stocks Securing the 2026 Choke Points - GlobeNewswire
Oncolytics Biotech Inc. Appoints New Executive Team Members to Enhance Strategic Operations and Clinical Development - Quiver Quantitative
Where are the Opportunities in (ONC) (ONC:CA) - Stock Traders Daily
Stop Loss: How Oncolytics Biotech Inc stock reacts to Fed rate cutsEarnings Risk Report & Free Reliable Trade Execution Plans - Bộ Nội Vụ
Oncolytics Biotech Advances Immunotherapy for Accelerated Approval in Oncology - Intellectia AI
Oncolytics Biotech (ONCY) leadership strengthens as Pelareorep advances - MSN
Oncolytics Biotech Data Signal Registration Path for Pelareorep Combo in Third-Line Anal Cancer - TipRanks
Pelareorep-atezolizumab shows promising results in anal cancer - Investing.com
Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026 - The Malaysian Reserve
The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff - The Globe and Mail
Oncolytics (ONCY) Presents Promising Data for SCAC Treatment - GuruFocus
Oncolytics Biotech® Announces Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer - The Manila Times
Oncolytics Biotech Reports Promising Clinical Data for Pelareorep-Atezolizumab Combination in Third-Line Metastatic Anal Cancer - Quiver Quantitative
Oncolytics Biotech® Announces Updated Clinical Data From Goblet Cohort 4 Demonstrating Activity Of Pelareorep Plus Atezolizumab In Third-Line Anal Cancer - TradingView — Track All Markets
Oncolytics Biotech Inc Stock (ONCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):